Compare TFIN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFIN | TSHA |
|---|---|---|
| Founded | 1981 | 2019 |
| Country | United States | United States |
| Employees | 1450 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | TFIN | TSHA |
|---|---|---|
| Price | $73.02 | $6.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $66.20 | $11.63 |
| AVG Volume (30 Days) | 205.2K | ★ 2.3M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $7.27 | N/A |
| Revenue Next Year | $11.31 | $1,152.42 |
| P/E Ratio | $66.31 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $46.43 | $2.25 |
| 52 Week High | $77.84 | $7.30 |
| Indicator | TFIN | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 65.06 |
| Support Level | $60.93 | $4.39 |
| Resistance Level | $77.84 | $6.76 |
| Average True Range (ATR) | 2.45 | 0.38 |
| MACD | -0.18 | 0.11 |
| Stochastic Oscillator | 54.18 | 93.77 |
Triumph Financial Inc is a financial holding company based in the United States. Along with its subsidiaries, the company operates in four reportable segments: Banking, Factoring, Payments, and Intelligence. The Banking segment, which generates maximum revenue, includes the operations of TBK Bank, offering traditional banking services. The Factoring segment provides working capital solutions to the trucking industry through the purchase of invoices generated by carriers at a discount. The Payments segment provides payment, audit, and other banking services for the over-the-road trucking industry, and the Intelligence segment operates to turn the over-the-road trucking data collected through the services offered into actionable insights for its customers.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.